
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:creator id="https://plus.cobiss.net/cobiss/sr/sr/conor/106302217">Çelik, Mevlüt</dc:creator>
  <dc:creator id="https://orcid.org/0000-0003-0984-9011 https://plus.cobiss.net/cobiss/sr/sr/conor/106163721">Milojević, Milan</dc:creator>
  <dc:creator>Durko, Andras P.</dc:creator>
  <dc:creator>Oei, Frans B. S.</dc:creator>
  <dc:creator>Mahtab, Edris A. F.</dc:creator>
  <dc:creator>Bogers, Ad J. J. C.</dc:creator>
  <dc:date>2021</dc:date>
  <dc:source>Journal of cardiovascular development and disease 8(4)</dc:source>
  <dc:title xml:lang="eng">Asymptomatic patients with severe aortic stenosis and the impact of intervention</dc:title>
  <dc:language>eng</dc:language>
  <dc:identifier>https://unilib.phaidrabg.rs/o:3160</dc:identifier>
  <dc:identifier>doi:10.3390/jcdd8040035</dc:identifier>
  <dc:identifier>cobiss:128518665</dc:identifier>
  <dc:identifier>ISSN: 2308-3425</dc:identifier>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/legalcode</dc:rights>
  <dc:subject xml:lang="eng">Key words: aortic valve replacement, aortic stenosis, asymptomatic, early surgery, watchful waiting</dc:subject>
  <dc:format>application/pdf</dc:format>
  <dc:format>730138 bytes</dc:format>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:description xml:lang="eng">ABSTRACT: Objectives the exact timing of aortic valve replacement (AVR) in asymptomatic patients with severe aortic stenosis (AS) remains a matter of debate. Therefore, we described the natural history of asymptomatic patients with severe AS, and the effect of AVR on long-term survival.
METHODS: Asymptomatic patients who were found to have severe AS between June 2006 and May 2009 were included. Severe aortic stenosis was defined as peak aortic jet velocity Vmax ≥ 4.0 m/s or
aortic valve area (AVA) ≤ 1 cm2. Development of symptoms, the incidence of AVR, and all-cause mortality were assessed. Results: A total of 59 asymptomatic patients with severe AS were followed, with a mean follow-up of 8.9 ± 0.4 years. A total of 51 (86.4%) patients developed AS related
symptoms, and subsequently 46 patients underwent AVR. The mean 1-year, 2-year, 5-year, and 10-year overall survival rates were higher in patients receiving AVR compared to those who did not undergo AVR during follow-up (100%, 93.5%, 89.1%, and 69.4%, versus 92.3%, 84.6%, 65.8%,
and 28.2%, respectively; p &lt; 0.001). Asymptomatic patients with severe AS receiving AVR during follow-up showed an incremental benefit in survival of up to 31.9 months compared to conservatively managed patients (p = 0.002). CONCLUSIONS: The majority of asymptomatic patients turn symptomatic during follow-up. AVR during follow-up is associated with better survival in asymptomatic severe AS patients.</dc:description>
</oai_dc:dc>
